Identification of immune response against HPV and P53 antigen in patients with a squamouscell tumour arising from the head& neck regio

Recruiting

• Conditions: cancer; 10027655

• Registration Number: NL-OMON50415
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

Patients will be eligible if they fulfil all of the following criteria:
- The patient has histologically proven HNSCC.
-. The patient is at least 18 years old.

Exclusion Criteria

No histological proven HNSCC
Younger than 18 years

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The presence, number, type and specificity of tumour-specific immune response<br /><br>in the peripheral blood, tumour-draining lymph nodes and the tumour of patients<br /><br>with different types of HNSCC.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary objectives of this study are to assess:<br /><br>- The potential rise in HPV16 positive HNSCC in the Netherlands during the last<br /><br>decades.<br /><br>- Tumour-specific immunity in relation to chemotherapy.<br /><br>- The relation between tumour-specific immunity and clinical outcome.</p><br>